Complete Response: Lymphoma Trial A Success For Five Patients

A trans-Atlantic study to evaluate an antibody for treatment of B-cell non-Hodgkins lymphoma is still almost three years from completing patient follow-up, but already it has succeeded beyond expectations in the form of five patients declared disease-free a year and counting.

The Phase II trial involved a CD19 antibody that was tested at 26 sites — 22 in Europe and four in the United States. Ninety-two patients enrolled in the study, which set out to evaluate the compound’s efficacy in treating four NHL subtypes: FL (follicular lymphoma), DLBCL (diffuse large B-cell lymphoma), MCL (mantle cell lymphoma), plus a fourth, a type of indolent NHL.